Aurinia PharmaceuticalsAUPH
About: Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
Employees: 300
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
100% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 2 (+1) [Q1 2025]
86% more call options, than puts
Call options by funds: $14.4M | Put options by funds: $7.71M
85% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 20
14% more repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 58
7% more funds holding
Funds holding: 197 [Q4 2024] → 210 (+13) [Q1 2025]
4.78% more ownership
Funds ownership: 40.37% [Q4 2024] → 45.14% (+4.78%) [Q1 2025]
4% less capital invested
Capital invested by funds: $519M [Q4 2024] → $499M (-$20.5M) [Q1 2025]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
HC Wainwright & Co. Arthur He | 86%upside $17 | Buy Assumed | 30 Jul 2025 |
Financial journalist opinion
Based on 3 articles about AUPH published over the past 30 days









